New tool helps identify prostate cancer patients with highest risk of death
Wednesday, October 5, 2011 - 21:30
in Health & Medicine
After a prostate cancer patient receives radiation treatment, his doctor carefully monitors the amount of prostate-specific antigen, or PSA, in his blood. An increase in PSA, called biochemical failure, is the first detectable sign of the cancer's return to the prostate. A researcher have found that the time between the last radiation treatment and biochemical failure can accurately predict a patient's risk of death of prostate cancer.